Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LJN452 in adults with non-alcoholic steatohepatitis
NL-OMON46032Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tropifexor in metabolic dysfunction-associated steatohepatitis (MASH), sponsored by Novartis. Started May 2017; status: active, not recruiting.
02
Drugs
tropifexor
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NL-OMON46032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46032.